Anti-Aging & Wellness

• ACTH(4-10) Analogue: Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, developed 1982 Russian Academy, ACTH(4-7) + Pro-Gly-Pro extension for metabolic stability, 800+ publications, no hormonal activity
• Multi-Modal Neuroprotection: BDNF upregulation (1.4× protein, 3× mRNA hippocampus), monoamine modulation (180% 5-HIAA), copper chelation (K_D 1.3×10⁻¹⁵ M), anti-amyloid activity, transcriptomic ischemia protection
• Clinical Status: Russian FDA approved, List of Vital & Essential Drugs 2011, Phase I-II trials 1990-1996, extensive clinical use for stroke/cognitive disorders/optic neuropathy, low toxicity profile

• Master Antioxidant Tripeptide: L-γ-Glu-L-Cys-Gly sequence, ≥98% purity
• Cellular Redox Homeostasis: Primary intracellular thiol buffer (0.5-10 mM)
• Phase II Detoxification: GST-mediated conjugation and xenobiotic metabolism studies

• Triple-Peptide Blend: BPC-157 + TB-500 + GHK-Cu for comprehensive tissue regeneration
• Multi-Phase Coverage: Inflammation, angiogenesis, cell migration, and matrix remodeling
• Research Formulation: 50mg total, ≥98% purity per component, lyophilized powder

GLOW Blend 50mg research peptide for laboratory studies. Pharmaceutical-grade cosmetic peptide blend for in-vitro research only. Not for human consumption.

• Quad-Peptide Blend: BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg + KPV 10mg (80mg total)
• Enhanced Anti-Inflammatory: KPV addition for NF-κB pathway inhibition and cytokine control
• Comprehensive Regeneration: Cytoprotection, angiogenesis, collagen synthesis, and inflammation modulation

• Advanced Quad-Peptide Research Formulation: BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg + KPV 10mg (80mg total), extends GLOW Blend with KPV for enhanced inflammation modulation
• Comprehensive Repair Cascade: BPC-157 (cytoprotection, VEGFR2 activation), TB-500 (cell migration, angiogenesis), GHK-Cu (collagen synthesis, 4,000+ gene modulation), KPV (NF-κB inhibition, anti-inflammatory signaling)
• KPV Anti-Inflammatory Mechanism: C-terminal tripeptide of α-MSH, NF-κB pathway inhibition, TNF-α/IL-1β/IL-6 suppression, NO melanotropic effects (lacks melanocortin core sequence required for MC1R activation)